Type 2 Diabetes

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

This episode covers the recent commercial availability of the Pivot patch pump and the upcoming 7-day bolus patch from CeQur.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

This episode covers recent approvals and updated indications allowing more treatment options for children with diabetes.

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

Fonseca discusses substantially lower persistence and adherence with GLP-1s in real-world practice, highlighting methods for clinicians to address this.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

Shaminie Athinarayanan, PhD, discusses her recent study investigating the role of carbohydrate reduction in patients with obesity currently going through menopause.

Lance Sloan, MD, discusses his recent sub-analysis of the CATALYST trial, investigating whether hypercortisolism limits the efficacy of GLP-1s.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Vivian Fonseca, MD, explains data showing nearly half of patients with T2D discontinued GLP-1 therapy within 1 year, reducing their likelihood of achieving weight loss and HbA1c goals.

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.